New anticoagulants for the prevention of deep venous thrombosis: Time to consider cost effectiveness?

PharmacoEconomics

Volumn 27, Issue 10, 2009, Pages 793-795

  Apostolakis, Stavros ^a   Shantsila, Eduard ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; DABIGATRAN ETEXILATE; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; XARELTO; XIMELAGATRAN;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; HUMAN; LIVER INJURY; NOTE; PRIORITY JOURNAL; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BENZIMIDAZOLES; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; MORPHOLINES; PYRIDINES; THIOPHENES; VENOUS THROMBOSIS;

EID: 70349925984     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11313780-000000000-00000     Document Type: Note

References (12)

1. Geerts WH, Bergqvist D, Pineo GF, et al., American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008; 133: 381S-453S
2. Eikelboom JW, Karthikeyan G, Fagel N, et al. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 2009; 135: 513-520
3. Eriksson BI, Dahl OE, Rosencher N, et al., RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956
4. Eriksson BI, Dahl OE, Rosencher N, et al., RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185 (Pubitemid 47617868)
5. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty: a meta-analysis. Thromb Haemost 2009; 101: 77-85
6. Turpie AG, Lassen MR, Davidson BL, et al., for the RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009 May 16; 373 (9676): 1673-1680
7. Spyropoulos AC. Brave new world: the current and future use of novel anticoagulants. Thromb Res 2008; 123 Suppl. 1: S29-35
8. Khoo CW, Tay KH, Shantsila E, et al. Novel oral anticoagulants. Int J Clin Pract 2009; 63: 630-641
9. McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009; 27 (10): 829-846
10. Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 2007; 98: 234-242 (Pubitemid 47074201)
11. Fisher WD, Eriksson BI, Bauer KA, et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost 2007; 97: 931-937
12. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-461